Abstract
Background. Metformin is widely used as a first-line antihyperglycemic therapy in patients with type 2 diabetes mellitus (T2DM); however, individual variability in treatment response remains an important clinical issue. Genetic variations in the solute carrier family 22 member 1 (SLC22A1) gene, encoding the organic cation transpor­ter 1 (OCT1), may influence metformin pharmacokinetics and metabolic effects. The purpose of this study was to eva­luate the potential role of the SLC22A1 rs628031 A>G (Met408Val) polymorphism in the pathogenetic mechanisms of hormonal and metabolic responses to antihyperglycemic therapy in patients with T2DM and obesity. Materials and methods. The study included 61 patients with T2DM aged 28–80 years (35 men and 26 women) with metabolic syndrome and obesity (body mass index ≥ 30 kg/m2). All patients received oral antihyperglycemic therapy, including metformin, sulfonylureas, or their combinations. According to the antihyperglycemic therapy received, the patients were retrospectively divided into two groups: those receiving metformin-based therapy and those treated with other glucose-lowering agents (sulfonylureas or their combinations without metformin). Clinical, anthropometric, biochemi­cal, hormonal, and metabolic parameters were assessed, including carbohydrate and lipid metabolism indices, liver function markers, adipokine profile, and oxidative stress parameters. Genotyping of the SLC22A1 rs628031 A>G polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism analysis with MscI restriction enzyme. Results. Metformin-based therapy was associated with favorable changes in glycemic control, lipid profile, adipokine status, and oxidative stress markers in patients with T2DM and obesity. Carriers of the AG genotype of the SLC22A1 rs628031 polymorphism receiving metformin demonstrated significantly lower levels of low-density lipoprotein cholesterol, total cholesterol, omentin, osteoprotegerin, alanine aminotransferase, and aspartate aminotransferase compared with other genotype groups. At the same time, AG genotype carriers showed higher omentin and osteoprotegerin concentrations compared with AA genotype carriers, suggesting genotype-dependent modulation of metformin-associated metabolic effects. Conclusions. The obtained results indicate that the SLC22A1 rs628031 A>G polymorphism may contribute to variability in hormonal and metabolic responses to metformin therapy in patients with T2DM and obesity. Genetic differences in OCT1 function may influence lipid metabolism, adipokine regulation, liver homeostasis, and potentially bone-related metabolic processes. Assessment of SLC22A1 genetic variants may contribute to the development of personalized approaches for optimizing antihyperglycemic therapy and improving metabolic outcomes in patients with diabetes and metabolic disorders.

This publication has 28 references indexed in Scilit: